Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL776263 | 0.82 | LAP3 (0.36) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL11745106 | 0.80 | LAP3 (0.34) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL1251447 | 0.80 | PPARD (0.35) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL5665071 | 0.78 | LAP3 (0.33) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL11304243 | 0.78 | MMP1 (0.36) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL2118428 | 0.78 | LAP3 (0.38) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL10794621 | 0.78 | LAP3 (0.33) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL5032698 | 0.78 | LAP3 (0.33) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL3090613 | 0.78 | METAP1 (0.36) | LAP3METAP1SMPD1PPARD | |
| SCHEMBL1376856 | 0.77 | PPARD (0.52) | LAP3METAP1MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194524-A1 | Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof | JERINI AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1703912-A1 | COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF | Jerini AG (DE) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005063259-A1 | COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF | JERINI AG (DE) | 2005-07-14 | — | — | WO | disclosed |
| US-6252084-B1 | THERAPY FOR SEPSIS SHOCK | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0620215-B1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | LILLY CO ELI (US) | 1999-08-18 | — | — | EP | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194524-A1 | Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof | CCNB1, CCNB2, CCNA1 | LAP3 4106/4885METAP1 3408/4885MMP1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.